The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy

Por Kortylewski, Marcin, Pal, Sumanta K
Publicado em 2014

Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer

Por Pal, Sumanta K., Kortylewski, Marcin
Publicado no Oncoimmunology (2015)

Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in NSCLC

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer

Por Pal, Sumanta K., Stein, C. A.
Publicado em 2012

Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

Por Pal, Sumanta K., Haas, Naomi B.
Publicado em 2014

Differentiating mTOR Inhibitors in Renal Cell Carcinoma

Por Pal, Sumanta K., Quinn, David I.
Publicado no Cancer Treat Rev (2013)

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Por Pal, Sumanta K., Lewis, Brian, Sartor, Oliver
Publicado em 2012

Radium-223 in metastatic castration resistant prostate cancer

Por Vuong, Winston, Sartor, Oliver, Pal, Sumanta K
Publicado em 2014

Management of localized prostate cancer: the pendulum swings (back to the middle)

Por Vuong, Winston, Sartor, Oliver, Pal, Sumanta K
Publicado em 2014

Lessons learned from Avastin

Por Mortimer, Joanne, Zonder, Helene, Pal, Sumanta K.
Publicado no Cancer Control (2012)

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era

Por Pal, Sumanta K., Nelson, Rebecca A., Vogelzang, Nicholas
Publicado em 2013

Enzalutamide for the treatment of prostate cancer

Por Pal, Sumanta K., Stein, Cy A., Sartor, Oliver
Publicado em 2013

A New Age for Vaccine Therapy in Renal Cell Carcinoma

Por Pal, Sumanta K., Hu, Adriana, Figlin, Robert A.
Publicado em 2013

A Gap in Disease-Specific Survival Between Younger and Older Adults With De Novo Metastatic Renal Cell Carcinoma: Results of a SEER Database Analysis

Por Nelson, Rebecca A., Vogelzang, Nicholas, Pal, Sumanta K.
Publicado em 2013

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

Por Alex, Anitha B., Pal, Sumanta K., Agarwal, Neeraj
Publicado no Ther Adv Med Oncol (2016)

Tivozanib: Current status and future directions in the treatment of solid tumors

Por Pal, Sumanta K., Bergerot, Paulo G., Figlin, Robert A.
Publicado em 2012

Development of PROSTVAC immunotherapy in prostate cancer

Por Singh, Parminder, Pal, Sumanta K, Alex, Anitha, Agarwal, Neeraj
Publicado no Future Oncol (2015)

Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

Por Pal, Sumanta K., Vanderwalde, Ari, Hurria, Arti, Figlin, Robert A.
Publicado no Drugs Aging (2011)

Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer

Por Pal, Sumanta K., Ruel, Nora H., Wilson, Timothy G., Yuh, Bertram E.
Publicado em 2012